SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
Seriously 'Sinister' Big Pharma: Opioid Maker Bankrolls Opposition to Pro-Pot Referendum
"You have a company using profits from the sale of what has been called 'the most potent and dangerous opioid on the market' to prevent adults from using a far less harmful substance."
Sep 09, 2016
It has been revealed that the maker of a powerful, addictive opioid drug is bankrolling the opposition to the effort to legalize and regulate marijuana for recreational use in Arizona.
The Phoenix New Times reported Thursday that Insys Therapeutics, the company behind the fentanyl-based medication Subsys, made a $500,000 donation to the group Arizonans for Responsible Drug Policy (ARDP), which is leading the campaign against Proposition 205.
On the ballot in November, Prop. 205 would allow people 21 years of age or older to possess up to one ounce of marijuana and grow up to six plants in their homes as well as establish a department to regulate the drug's cultivation and sale.
It appears that Insys is trying to "eliminate the competition," according to the New Times, which noted that the company "expects to soon launch a pharmaceutical version of THC, the main psychoactive ingredient in cannabis."
What's more, Insys is currently facing numerous state investigations for deceptively marketing and selling Subsys, which is intended to treat cancer pain, and coercing doctors to promote it to patients for off-label uses. Fentanyl is estimated to be 80 times as potent as morphine and hundreds of times more potent than heroin, according to the Centers for Disease Control and Prevention, and may be fatal to users.
"It's hard to imagine a more sinister donor than Insys Therapeutics Inc. in the eyes of pot legalization proponents, who long have claimed drug companies want to keep cannabis illegal to corner the market for drugs, some addictive and dangerous, that relieve pain and other symptoms," U.S. News & World Report wrote Thursday, summarizing the dynamic.
Responding to the news, J.P. Holyoak, chair of the Prop. 205 proponent group Campaign to Regulate Marijuana Like Alcohol, issued a press statement slamming the opposition to keeping the donation from "one of the more unscrupulous members of Big Pharma."
"You have a company using profits from the sale of what has been called 'the most potent and dangerous opioid on the market' to prevent adults from using a far less harmful substance," Holyoak said.
He also pointed out their development of synthetic 'pharmaceutical cannabinoids,' and said, "It appears they are trying to kill a non-pharmaceutical market for marijuana in order to line their own pockets."
"Our opponents have made a conscious decision to associate with this company. They are now funding their campaign with profits from the sale of opioids -- and maybe even the improper sale of opioids," Holyoak continued. "Any time an ad airs against Prop. 205, the voters should know that it was paid for by highly suspect Big Pharma actors."
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Lauren McCauley
Lauren McCauley is a former senior editor for Common Dreams covering national and international politics and progressive news. She is now the Editor of Maine Morning Star. Lauren also helped produce a number of documentary films, including the award-winning Soundtrack for a Revolution and The Hollywood Complex, as well as one currently in production about civil rights icon James Meredith. Her writing has been featured on Newsweek, BillMoyers.com, TruthDig, Truthout, In These Times, and Extra! the newsletter of Fairness and Accuracy in Reporting. She currently lives in Kennebunk, Maine with her husband, two children, a dog, and several chickens.
2016 ballot issuesarizonabig pharmacenters for disease control (cdc)election 2016marijuanapublic health
It has been revealed that the maker of a powerful, addictive opioid drug is bankrolling the opposition to the effort to legalize and regulate marijuana for recreational use in Arizona.
The Phoenix New Times reported Thursday that Insys Therapeutics, the company behind the fentanyl-based medication Subsys, made a $500,000 donation to the group Arizonans for Responsible Drug Policy (ARDP), which is leading the campaign against Proposition 205.
On the ballot in November, Prop. 205 would allow people 21 years of age or older to possess up to one ounce of marijuana and grow up to six plants in their homes as well as establish a department to regulate the drug's cultivation and sale.
It appears that Insys is trying to "eliminate the competition," according to the New Times, which noted that the company "expects to soon launch a pharmaceutical version of THC, the main psychoactive ingredient in cannabis."
What's more, Insys is currently facing numerous state investigations for deceptively marketing and selling Subsys, which is intended to treat cancer pain, and coercing doctors to promote it to patients for off-label uses. Fentanyl is estimated to be 80 times as potent as morphine and hundreds of times more potent than heroin, according to the Centers for Disease Control and Prevention, and may be fatal to users.
"It's hard to imagine a more sinister donor than Insys Therapeutics Inc. in the eyes of pot legalization proponents, who long have claimed drug companies want to keep cannabis illegal to corner the market for drugs, some addictive and dangerous, that relieve pain and other symptoms," U.S. News & World Report wrote Thursday, summarizing the dynamic.
Responding to the news, J.P. Holyoak, chair of the Prop. 205 proponent group Campaign to Regulate Marijuana Like Alcohol, issued a press statement slamming the opposition to keeping the donation from "one of the more unscrupulous members of Big Pharma."
"You have a company using profits from the sale of what has been called 'the most potent and dangerous opioid on the market' to prevent adults from using a far less harmful substance," Holyoak said.
He also pointed out their development of synthetic 'pharmaceutical cannabinoids,' and said, "It appears they are trying to kill a non-pharmaceutical market for marijuana in order to line their own pockets."
"Our opponents have made a conscious decision to associate with this company. They are now funding their campaign with profits from the sale of opioids -- and maybe even the improper sale of opioids," Holyoak continued. "Any time an ad airs against Prop. 205, the voters should know that it was paid for by highly suspect Big Pharma actors."
Lauren McCauley
Lauren McCauley is a former senior editor for Common Dreams covering national and international politics and progressive news. She is now the Editor of Maine Morning Star. Lauren also helped produce a number of documentary films, including the award-winning Soundtrack for a Revolution and The Hollywood Complex, as well as one currently in production about civil rights icon James Meredith. Her writing has been featured on Newsweek, BillMoyers.com, TruthDig, Truthout, In These Times, and Extra! the newsletter of Fairness and Accuracy in Reporting. She currently lives in Kennebunk, Maine with her husband, two children, a dog, and several chickens.
It has been revealed that the maker of a powerful, addictive opioid drug is bankrolling the opposition to the effort to legalize and regulate marijuana for recreational use in Arizona.
The Phoenix New Times reported Thursday that Insys Therapeutics, the company behind the fentanyl-based medication Subsys, made a $500,000 donation to the group Arizonans for Responsible Drug Policy (ARDP), which is leading the campaign against Proposition 205.
On the ballot in November, Prop. 205 would allow people 21 years of age or older to possess up to one ounce of marijuana and grow up to six plants in their homes as well as establish a department to regulate the drug's cultivation and sale.
It appears that Insys is trying to "eliminate the competition," according to the New Times, which noted that the company "expects to soon launch a pharmaceutical version of THC, the main psychoactive ingredient in cannabis."
What's more, Insys is currently facing numerous state investigations for deceptively marketing and selling Subsys, which is intended to treat cancer pain, and coercing doctors to promote it to patients for off-label uses. Fentanyl is estimated to be 80 times as potent as morphine and hundreds of times more potent than heroin, according to the Centers for Disease Control and Prevention, and may be fatal to users.
"It's hard to imagine a more sinister donor than Insys Therapeutics Inc. in the eyes of pot legalization proponents, who long have claimed drug companies want to keep cannabis illegal to corner the market for drugs, some addictive and dangerous, that relieve pain and other symptoms," U.S. News & World Report wrote Thursday, summarizing the dynamic.
Responding to the news, J.P. Holyoak, chair of the Prop. 205 proponent group Campaign to Regulate Marijuana Like Alcohol, issued a press statement slamming the opposition to keeping the donation from "one of the more unscrupulous members of Big Pharma."
"You have a company using profits from the sale of what has been called 'the most potent and dangerous opioid on the market' to prevent adults from using a far less harmful substance," Holyoak said.
He also pointed out their development of synthetic 'pharmaceutical cannabinoids,' and said, "It appears they are trying to kill a non-pharmaceutical market for marijuana in order to line their own pockets."
"Our opponents have made a conscious decision to associate with this company. They are now funding their campaign with profits from the sale of opioids -- and maybe even the improper sale of opioids," Holyoak continued. "Any time an ad airs against Prop. 205, the voters should know that it was paid for by highly suspect Big Pharma actors."
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.